These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2534945)

  • 21. Ondansetron, a new antiemetic therapy for oncology. An overview.
    Lip H
    Scand J Gastroenterol Suppl; 1990; 178():55-61. PubMed ID: 2148983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
    Marty M; Kleisbauer JP; Fournel P; Vergnenegre A; Carles P; Loria-Kanza Y; Simonetta C; de Bruijn KM
    Anticancer Drugs; 1995 Feb; 6 Suppl 1():15-21. PubMed ID: 7749165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antiemetic therapy with timiperone in cisplatin-induced vomiting].
    Tari K; Satake I; Kojima S; Owada F
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2848-52. PubMed ID: 3753027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ondansetron to prevent chemotherapy-induced vomiting.
    Drug Ther Bull; 1992 Mar; 30(6):21-3. PubMed ID: 1534293
    [No Abstract]   [Full Text] [Related]  

  • 25. [The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial].
    Zhou J; Zeng W; Zhang P
    Zhonghua Zhong Liu Za Zhi; 1995 May; 17(3):215-8. PubMed ID: 7656830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multi-drug antiemetic treatment and effect of treatment duration of concurrent steroids--for complete control of chemotherapy-induced nausea/vomiting in gynecological cancer].
    Fujii T; Nakata N; Shiroyama Y; Sawasaki T; Tanimoto H; Shigemasa K; Kioka H; Naito H
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2245-52. PubMed ID: 9422069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
    Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
    Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Emesis induced by cisplatin and sulfato-1, sulfato-1,2-diaminocyclohexane platinum in dogs and their antiemetics].
    Huo ML; Wang YS; Wang P; Xiang YS; Wang JG
    Zhongguo Yao Li Xue Bao; 1986 Mar; 7(2):182-4. PubMed ID: 2946163
    [No Abstract]   [Full Text] [Related]  

  • 30. Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatin-induced emesis in the ferret.
    Lau AH; Kan KK; Lai HW; Ngan MP; Rudd JA; Wai MK; Yew DT
    Eur J Pharmacol; 2005 Jan; 506(3):241-7. PubMed ID: 15627434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
    Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
    McMillan C; Dundee JW; Abram WP
    Br J Cancer; 1991 Nov; 64(5):971-2. PubMed ID: 1834156
    [No Abstract]   [Full Text] [Related]  

  • 33. Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen.
    Plezia PM; Alberts DS; Kessler J; Aapro MS; Graham V; Surwit EA
    Cancer Treat Rep; 1984 Dec; 68(12):1493-5. PubMed ID: 6542448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
    Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
    Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ondansetron HCL (Zofran TM, Glaxo).
    Frankiewicz V; Farrington E
    Pediatr Nurs; 1992; 18(4):385-6. PubMed ID: 1387704
    [No Abstract]   [Full Text] [Related]  

  • 36. Publication of unethical studies on the treatment of chemotherapy-induced emesis.
    Roila F; Tonato M; Del Favero A
    J Clin Oncol; 1991 May; 9(5):891-3. PubMed ID: 1826740
    [No Abstract]   [Full Text] [Related]  

  • 37. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis.
    Cunningham D; Turner A; Hawthorn J; Rosin RD
    Lancet; 1989 Jun; 1(8650):1323. PubMed ID: 2566845
    [No Abstract]   [Full Text] [Related]  

  • 38. Ondansetron: A new concept in the management of emesis. Proceedings from an investigators meeting. Seattle, Washington, September 1990.
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-78. PubMed ID: 1387244
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose and long-term use of ondansetron.
    Vohra S; Juricic J
    Ann Pharmacother; 1992 Jan; 26(1):128-9. PubMed ID: 1535002
    [No Abstract]   [Full Text] [Related]  

  • 40. Ondansetron in the treatment of theophylline overdose.
    Brown SG; Prentice DA
    Med J Aust; 1992 Apr; 156(7):512. PubMed ID: 1532627
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.